18 research outputs found
Achieving energy efficiency using novel scalar multiplication based ECC for android devices in Internet of Things environments
Impact of the Hypoxia-Inducible Factor-1 Â (HIF1A) Pro582Ser Polymorphism on Diabetes Nephropathy
Abstract 5588: Clinical and pharmacodynamic responses to a modified whole tumor cell immunotherapy in patients with advanced breast cancer from two phase I-IIa trials
Abstract SV-BR-1-GM is a GM-CSF secreting breast cancer cell line that also expresses HLA class I & II antigens. Irradiated SV-BR-1-GM is used in a regimen including pre-dose low-dose cyclophosphamide and post-dose local interferon-α2b. The SV-BR-1-GM regimen has been used alone (âMonotherapyâ study ClinicalTrials.gov NCT03066947) and in combination with immune checkpoint inhibitors (ongoing combination study ClinicalTrials.gov identifier NCT03328026). Here we report regression of metastatic breast cancer and pharmacodynamic analysis with immunologic correlates. 23 patients with advanced breast cancer refractory to standard therapies were treated with the SV-BR-1-GM regimen in the monotherapy trial with cycles every 2 weeks for the first month and then monthly. The combination study is evaluating the SV-BR-1-GM regimen with checkpoint inhibitors (PD-1 inhibitors pembrolizumab or INCMGA00012) with cycles every 3 weeks (11 patients have been dosed to date). Pharmacodynamic analyses include delayed-type hypersensitivity (DTH), antibodies against SV-BR-1 (precursor of SV-BR-1-GM), blood lymphocyte proliferation (determined using flow cytometry), circulating cytokines in sera and cytokine secretion (Luminex based assays) following stimulation with peptides of antigens expressed in SV-BR-1-GM cells (HER2 and PRAME). In the monotherapy study, tumor regression was seen in 3 patients. 21 patients developed measurable DTH signifying cellular immunity. Blood lymphocytes from responders after treatment showed increased proliferation and cytokine secretion (GM-CSF, IL-2, IL-21) - following stimulation with HER2 and PRAME peptides. Differential serum cytokine levels were observed (CD40L, MCP-1, IL-1RA) in 5 patients. Increased antibody levels compared to baseline were observed in 6 of the 12 patients assessed. Patients with objective tumor regression had the most pronounced responses. In the combination therapy study, 2 patients have shown objective evidence of tumor regression, including one patient with liver metastases, which decreased by 25%, and one patient with adrenal and dural metastases (29% reduction in target lesion). Both patients had Grade II tumors, similar to the tumor from which SV-BR-1-GM was derived. These observations confirm the ability of the SV-BR-1-GM regimen to elicit regression of far advanced refractory metastatic breast cancer. No serious toxicities clearly attributed to the SV-BR-1-GM regimen were observed. Pharmacodynamic analysis of humoral and cell-mediated immune responses showed notable upregulation, the strongest responses being seen in those with measurable clinical regression. Patients with Grade I or II tumors appeared more likely to respond. Citation Format: Vivekananda G. Sunkari, Jacqueline Galeas, Shaker R. Dakhil, Jarrod Holmes, Saveri Bhattacharya, Carmen J. Calfa, Ajay Kundra, Daniel L. Adams, Diane DaSilva, George E. Peoples, Charles L. Wiseman, William V. Williams, Markus D. Lacher. Clinical and pharmacodynamic responses to a modified whole tumor cell immunotherapy in patients with advanced breast cancer from two phase I-IIa trials [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5588
Correction of Immunoendocrine Disorders in Patients with Ischemic Heart Disease Using Low-intensity Microwave Therapy
Conditional Bus Priority at Signalized Intersections: Better Service with Less Traffic Disruption
Stabilization of HIF-1α is critical to improve wound healing in diabetic mice
Relative hypoxia is essential in wound healing since it normally plays a pivotal role in regulation of all the critical processes involved in tissue repair. Hypoxia-inducible factor (HIF) 1α is the critical transcription factor that regulates adaptive responses to hypoxia. HIF-1α stability and function is regulated by oxygen-dependent soluble hydroxylases targeting critical proline and asparaginyl residues. Here we show that hyperglycemia complexly affects both HIF-1α stability and activation, resulting in suppression of expression of HIF-1 target genes essential for wound healing both in vitro and in vivo. However, by blocking HIF-1α hydroxylation through chemical inhibition, it is possible to reverse this negative effect of hyperglycemia and to improve the wound healing process (i.e., granulation, vascularization, epidermal regeneration, and recruitment of endothelial precursors). Local adenovirus-mediated transfer of two stable HIF constructs demonstrated that stabilization of HIF-1α is necessary and sufficient for promoting wound healing in a diabetic environment. Our findings outline the necessity to develop specific hydroxylase inhibitors as therapeutic agents for chronic diabetes wounds. In conclusion, we demonstrate that impaired regulation of HIF-1α is essential for the development of diabetic wounds, and we provide evidence that stabilization of HIF-1α is critical to reverse the pathological process